Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 8 (August)

1. Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study.
   J Health Care Poor Underserved, 20(3): 721-8. [Abstract] [Full-text]
2. The cost of health care services provided to women enrolled in a community-based breast and cervical cancer screening program.
   J Health Care Poor Underserved, 20(3): 713-20. [Abstract] [Full-text]
3. Dosimetric parameters in partial breast irradiation through brachytherapy.
   Med Dosim, 34(3): 207-13. [Abstract] [Full-text]
4. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
   Cancer Cell, 16(2): 89-90. [Abstract] [Full-text]
5. Genotype-guided tamoxifen therapy: time to pause for reflection?
   Lancet Oncol, 10(8): 825-33. [Abstract] [Full-text]
6. Subcutaneous mastectomy with conservation of the nipple-areola skin: broadening the indications.
   Ann Surg, 250(2): 288-92. [Abstract] [Full-text]
7. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.
   Mol Cancer, 8: 49. [Abstract] [Full-text]
8. Tumor characterization with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice.
   Pharm Res, 26(9): 2202-8. [Abstract] [Full-text]
9. Reproductive health assessment for women with cancer: a pilot study.
   Am J Obstet Gynecol, 201(2): 191.e1-4. [Abstract] [Full-text]
10. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression.
    J Biol Chem, 284(32): 21209-17. [Abstract] [Full-text]
11. RGS16 inhibits breast cancer cell growth by mitigating phosphatidylinositol 3-kinase signaling.
    J Biol Chem, 284(32): 21719-27. [Abstract] [Full-text]
12. In vitro and in vivo anticancer activity of 2-deacetoxytaxinine J and synthesis of novel taxoids and their in vitro anticancer activity.
    Eur J Med Chem, 44(10): 3947-53. [Abstract] [Full-text]
13. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
    J Pain Symptom Manage, 38(2): 244-57. [Abstract] [Full-text]
14. Estrogen/isoflavone interactions in cynomolgus macaques (Macaca fascicularis).
    Am J Primatol, 71(9): 722-31. [Abstract] [Full-text]
15. Breast cancer in Chinese elderly women: pathological and clinical characteristics and factors influencing treatment patterns.
    Crit Rev Oncol Hematol, 71(3): 258-65. [Abstract] [Full-text]
16. Evaluation of a cancer exercise program: patient and physician beliefs.
    Psychooncology, 18(8): 898-902. [Abstract] [Full-text]
17. Sexual health issues in Sudanese women before and during hormonal treatment for breast cancer.
    Psychooncology, 18(8): 858-65. [Abstract] [Full-text]
18. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
    Psychooncology, 18(8): 811-21. [Abstract] [Full-text]
19. The role of illness representations in coping and health of patients treated for breast cancer.
    Psychooncology, 18(8): 849-57. [Abstract] [Full-text]
20. The religiosity/spirituality of Latina breast cancer survivors and influence on health-related quality of life.
    Psychooncology, 18(8): 831-40. [Abstract] [Full-text]
21. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.
    Genes Dev, 23(15): 1737-42. [Abstract] [Full-text]
22. RCP is a human breast cancer-promoting gene with Ras-activating function.
    J Clin Invest, 119(8): 2171-83. [Abstract] [Full-text]
23. Genomic amplicons target vesicle recycling in breast cancer.
    J Clin Invest, 119(8): 2123-7. [Abstract] [Full-text]
24. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    J Nucl Med, 50(8): 1340-8. [Abstract] [Full-text]
25. Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis.
    Cancer Lett, 283(2): 176-85. [Abstract] [Full-text]
26. Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.
    Cancer Lett, 283(2): 143-51. [Abstract] [Full-text]
27. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence.
    Int J Epidemiol, 38(4): 963-70. [Abstract] [Full-text]
28. Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids.
    Acta Pharmacol Sin, 30(8): 1169-76. [Abstract] [Full-text]
29. Spatial analysis of breast and cervical cancer incidence in small geographical areas in Cuba, 1999-2003.
    Eur J Cancer Prev, 18(5): 395-403. [Abstract] [Full-text]
30. Serum calcium and tumour aggressiveness in breast cancer: a prospective study of 7847 women.
    Eur J Cancer Prev, 18(5): 354-60. [Abstract] [Full-text]
31. Second primary breast cancer occurrence according to hormone receptor status.
    J Natl Cancer Inst, 101(15): 1058-65. [Abstract] [Full-text]
32. Physical activity levels among urban and rural women in south India and the risk of breast cancer: a case-control study.
    Eur J Cancer Prev, 18(5): 368-76. [Abstract] [Full-text]
33. Breast cancer screening participation among Turks and Moroccans in the Netherlands: exploring reasons for nonattendance.
    Eur J Cancer Prev, 18(5): 349-53. [Abstract] [Full-text]
34. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.
    Int J Cancer, 125(7): 1613-21. [Abstract] [Full-text]
35. Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF.
    Eur J Cancer Prev, 18(5): 416-23. [Abstract] [Full-text]
36. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
    Eur J Cancer Prev, 18(5): 361-7. [Abstract] [Full-text]
37. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
    Ann Oncol, 20(8): 1319-29. [Abstract] [Full-text]
38. FAK overexpression and p53 mutations are highly correlated in human breast cancer.
    Int J Cancer, 125(7): 1735-8. [Abstract] [Full-text]
39. DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin.
    Int J Cancer, 125(7): 1604-12. [Abstract] [Full-text]
40. A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection.
    Ann Oncol, 20(8): 1352-61. [Abstract] [Full-text]
41. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
    Ann Oncol, 20(8): 1344-51. [Abstract] [Full-text]
42. 'Cure' from breast cancer among two populations of women followed for 23 years after diagnosis.
    Ann Oncol, 20(8): 1331-6. [Abstract] [Full-text]
43. Combining systemic therapies with radiation in breast cancer.
    Cancer Treat Rev, 35(5): 409-16. [Abstract] [Full-text]
44. +331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer.
    Int J Cancer, 125(7): 1685-91. [Abstract] [Full-text]
45. Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India.
    Int J Cancer, 125(7): 1663-70. [Abstract] [Full-text]
46. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study.
    Eur J Cancer Prev, 18(5): 343-8. [Abstract] [Full-text]
47. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer.
    Cancer Treat Rev, 35(5): 463-74. [Abstract] [Full-text]
48. Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression.
    Mol Cell Biochem, 329(1): 115-20. [Abstract] [Full-text]
49. Surgical removal of the breast primary for patients presenting with metastases - where to go?
    Cancer Treat Rev, 35(5): 391-6. [Abstract] [Full-text]
50. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.
    Ann Oncol, 20(8): 1337-43. [Abstract] [Full-text]
51. Jordanian and Palestinian immigrant women's knowledge, affect, cultural attitudes, health habits, and participation in breast cancer screening.
    Health Care Women Int, 30(9): 768-82. [Abstract] [Full-text]
52. Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells.
    Apoptosis, 14(9): 1076-85. [Abstract] [Full-text]
53. Characterization of MCF mammary epithelial cells overexpressing the Arylhydrocarbon receptor (AhR).
    BMC Cancer, 9: 234. [Abstract] [Full-text]
54. The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors.
    Semin Oncol, 36(4): S55-68. [Abstract] [Full-text]
55. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2339-42. [Abstract] [Full-text]
56. Maternal pelvic size not predictive of daughter's breast cancer or ovarian cancer in a large Swedish cohort.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2333-5. [Abstract] [Full-text]
57. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2318-24. [Abstract] [Full-text]
58. Circulating estrogen metabolites and risk for breast cancer in premenopausal women.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2273-9. [Abstract] [Full-text]
59. Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports?
    Cancer Epidemiol Biomarkers Prev, 18(8): 2214-20. [Abstract] [Full-text]
60. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2207-13. [Abstract] [Full-text]
61. Ovarian carcinoma metastasis to the breast and imaging features with histopathologic correlation: a case report and review of the literature.
    Clin Breast Cancer, 9(3): 196-8. [Abstract] [Full-text]
62. Metastatic phyllodes tumor causing small-bowel obstruction.
    Clin Breast Cancer, 9(3): 193-5. [Abstract] [Full-text]
63. Radiologic characteristics and management of screen-detected metastatic carcinoid tumor of the breast: a case report.
    Clin Breast Cancer, 9(3): 189-92. [Abstract] [Full-text]
64. Primary squamous cell carcinoma of the breast: achieving long-term control with cisplatin-based chemotherapy.
    Clin Breast Cancer, 9(3): 187-8. [Abstract] [Full-text]
65. Visual impairment in myopic patients with breast cancer receiving adjuvant therapy with aromatase inhibitors.
    Clin Breast Cancer, 9(3): 184-6. [Abstract] [Full-text]
66. Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
    Clin Breast Cancer, 9(3): 178-83. [Abstract] [Full-text]
67. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.
    Clin Breast Cancer, 9(3): 173-7. [Abstract] [Full-text]
68. A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers.
    Clin Breast Cancer, 9(3): 166-72. [Abstract] [Full-text]
69. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
    Clin Breast Cancer, 9(3): 161-5. [Abstract] [Full-text]
70. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer.
    Clin Breast Cancer, 9(3): 155-60. [Abstract] [Full-text]
71. The Hedgehog signalling pathway as a therapeutic target in early breast cancer development.
    Expert Opin Ther Targets, 13(9): 1095-103. [Abstract] [Full-text]
72. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
    Nat Med, 15(8): 907-13. [Abstract] [Full-text]
73. Simultaneous integrated boost radiotherapy for bilateral breast: a treatment planning and dosimetric comparison for volumetric modulated arc and fixed field intensity modulated therapy.
    Radiat Oncol, 4: 27. [Abstract] [Full-text]
74. Race/Ethnicity has no effect on outcome for breast cancer patients treated at an academic center with a public hospital.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2157-61. [Abstract] [Full-text]
75. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis.
    Nat Med, 15(8): 960-6. [Abstract] [Full-text]
76. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
    J Clin Oncol, 27(23): 3749-56. [Abstract] [Full-text]
77. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    J Clin Oncol, 27(23): 3764-71. [Abstract] [Full-text]
78. Accuracy of breast cancer axillary lymph node treatment plans based on 2-dimensional imaging: what we should know before interpreting 2-dimensional treatment-planning era studies.
    Am J Clin Oncol, 32(4): 387-95. [Abstract] [Full-text]
79. Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression.
    J Proteome Res, 8(8): 4062-76. [Abstract] [Full-text]
80. Investigation of reading mode and relative sensitivity as factors that influence reader performance when using computer-aided detection software.
    Acad Radiol, 16(9): 1095-107. [Abstract] [Full-text]
81. Clinical MR-mammography: are computer-assisted methods superior to visual or manual measurements for curve type analysis? A systematic approach.
    Acad Radiol, 16(9): 1070-6. [Abstract] [Full-text]
82. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.
    J Proteome Res, 8(8): 4151-60. [Abstract] [Full-text]
83. Effect of the enhancement threshold on the computer-aided detection of breast cancer using MRI.
    Acad Radiol, 16(9): 1064-9. [Abstract] [Full-text]
84. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer.
    J Clin Oncol, 27(23): 3757-63. [Abstract] [Full-text]
85. Differences between current and historical breast cancer axillary lymph node irradiation based on arm position: implications for radiation oncologists.
    Am J Clin Oncol, 32(4): 381-6. [Abstract] [Full-text]
86. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.
    Am J Clin Oncol, 32(4): 369-74. [Abstract] [Full-text]
87. Lactation and incidence of premenopausal breast cancer: a longitudinal study.
    Arch Intern Med, 169(15): 1364-71. [Abstract] [Full-text]
88. Developing and testing a cost-assessment tool for cancer screening programs.
    Am J Prev Med, 37(3): 242-7. [Abstract] [Full-text]
89. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.
    Cell, 138(3): 592-603. [Abstract] [Full-text]
90. CT staging of loco-regional breast cancer recurrence. A worthwhile practice?
    Clin Radiol, 64(9): 885-90. [Abstract] [Full-text]
91. Pharmacotherapy of triple-negative breast cancer.
    Expert Opin Pharmacother, 10(13): 2081-93. [Abstract] [Full-text]
92. Triple-negative breast cancer: novel therapies and new directions.
    Maturitas, 63(4): 269-74. [Abstract] [Full-text]
93. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.
    Proc Natl Acad Sci U S A, 106(31): 12903-8. [Abstract] [Full-text]
94. Menopausal symptoms following breast cancer treatment: a qualitative investigation of cognitive and behavioural responses.
    Maturitas, 63(4): 336-40. [Abstract] [Full-text]
95. Why do Asian-American women have lower rates of breast conserving surgery: results of a survey regarding physician perceptions.
    BMC Public Health, 9: 246. [Abstract] [Full-text]
96. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation.
    Biochem Biophys Res Commun, 387(2): 381-6. [Abstract] [Full-text]
97. Attitudes and anticipated reactions to genetic testing for cancer among patients in Mexico City.
    Genet Test Mol Biomarkers, 13(4): 477-83. [Abstract] [Full-text]
98. Aromatase inhibitors in breast cancer.
    Maturitas, 63(4): 275-9. [Abstract] [Full-text]
99. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
    Proc Natl Acad Sci U S A, 106(31): 12909-14. [Abstract] [Full-text]
100. Fibrosarcomatous transformation in dermatofibrosarcoma protuberans of the breast--a case report.
     J Clin Ultrasound, 37(7): 420-3. [Abstract] [Full-text]
101. Estradiol-regulated microRNAs control estradiol response in breast cancer cells.
     Nucleic Acids Res, 37(14): 4850-61. [Abstract] [Full-text]
102. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
     Cancer, 115(16): 3631-9. [Abstract] [Full-text]
103. Radiochemotherapy in the treatment of breast cancer.
     Clin Oncol (R Coll Radiol), 21(7): 532-5. [Abstract] [Full-text]
104. The epidemiology of triple-negative breast cancer, including race.
     Cancer Causes Control, 20(7): 1071-82. [Abstract] [Full-text]
105. The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis.
     Cancer Causes Control, 20(7): 1091-105. [Abstract] [Full-text]
106. Patient and tumor characteristics associated with increased mortality in young women (< or =40 years) with breast cancer.
     J Surg Oncol, 100(3): 248-51. [Abstract] [Full-text]
107. Exposure to breast milk in infancy and risk of breast cancer.
     Cancer Causes Control, 20(7): 1083-90. [Abstract] [Full-text]
108. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
     Eur J Surg Oncol, 35(9): 936-41. [Abstract] [Full-text]
109. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
     J Neurooncol, 94(2): 229-34. [Abstract] [Full-text]
110. Sentinel node biopsy and quality of life measures in a Chinese population.
     Eur J Surg Oncol, 35(9): 921-7. [Abstract] [Full-text]
111. Spatial cluster analysis of early stage breast cancer: a method for public health practice using cancer registry data.
     Cancer Causes Control, 20(7): 1061-9. [Abstract] [Full-text]
112. Serum total cholesterol and the risk of breast cancer in postmenopausal Korean women.
     Cancer Causes Control, 20(7): 1055-60. [Abstract] [Full-text]
113. Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy.
     Eur J Surg Oncol, 35(9): 916-20. [Abstract] [Full-text]
114. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
     Eur J Surg Oncol, 35(9): 928-35. [Abstract] [Full-text]
115. Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype.
     Br J Cancer, 101(4): 673-83. [Abstract] [Full-text]
116. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer.
     Br J Cancer, 101(4): 605-14. [Abstract] [Full-text]
117. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.
     Br J Cancer, 101(4): 582-8. [Abstract] [Full-text]
118. Uracil-tegafur and tamoxifen vs cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in post-operative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study.
     Br J Cancer, 101(4): 598-604. [Abstract] [Full-text]
119. Mammography use among Black women: the role of electronic medical records.
     J Womens Health (Larchmt), 18(8): 1153-62. [Abstract] [Full-text]
120. Birth weight as a risk factor for breast cancer: a meta-analysis of 18 epidemiological studies.
     J Womens Health (Larchmt), 18(8): 1169-78. [Abstract] [Full-text]
121. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
     Br J Cancer, 101(4): 589-97. [Abstract] [Full-text]
122. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.
     Br J Cancer, 101(4): 666-72. [Abstract] [Full-text]
123. A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.
     Tumour Biol, 30(3): 148-59. [Abstract] [Full-text]
124. Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.
     J Transl Med, 7: 60. [Abstract] [Full-text]
125. Weight lifting in women with breast-cancer-related lymphedema.
     N Engl J Med, 361(7): 664-73. [Abstract] [Full-text]
126. Micrometastases or isolated tumor cells and the outcome of breast cancer.
     N Engl J Med, 361(7): 653-63. [Abstract] [Full-text]
127. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
     J Pathol, 219(1): 16-24. [Abstract] [Full-text]
128. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.
     J Pathol, 219(1): 1-2. [Abstract] [Full-text]
129. Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation.
     J Pathol, 219(1): 131-40. [Abstract] [Full-text]
130. Novel generating protective single nucleotide polymorphism barcode for breast cancer using particle swarm optimization.
     Cancer Epidemiol, 33(2): 147-54. [Abstract] [Full-text]
131. Patterns of HER2 testing in the management of primary breast cancer.
     Cancer Epidemiol, 33(2): 113-7. [Abstract] [Full-text]
132. hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation.
     Cancer Res, 69(16): 6624-32. [Abstract] [Full-text]
133. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.
     Cancer Res, 69(16): 6685-93. [Abstract] [Full-text]
134. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
     Cancer Res, 69(16): 6396-404. [Abstract] [Full-text]
135. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
     Cancer Res, 69(16): 6473-81. [Abstract] [Full-text]
136. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.
     Cancer Res, 69(16): 6713-20. [Abstract] [Full-text]
137. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
     Ann Surg Oncol, 16(9): 2470-8. [Abstract] [Full-text]
138. Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial.
     Ann Surg Oncol, 16(9): 2450-8. [Abstract] [Full-text]
139. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients.
     Ann Surg Oncol, 16(9): 2464-9. [Abstract] [Full-text]
140. Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty.
     Ann Surg Oncol, 16(9): 2442-9. [Abstract] [Full-text]
141. Feasibility of axillary reverse mapping during sentinel lymph node biopsy in breast cancer patients.
     Ann Surg Oncol, 16(9): 2459-63. [Abstract] [Full-text]
142. Implication of snoRNA U50 in human breast cancer.
     J Genet Genomics, 36(8): 447-54. [Abstract] [Full-text]
143. Genetics: breast cancer as an exemplar.
     Nurs Clin North Am, 44(3): 327-38. [Abstract] [Full-text]
144. Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility.
     Mol Cancer, 8: 58. [Abstract] [Full-text]
145. The distribution of lesions in 1-14-mm invasive breast carcinomas and its relation to metastatic potential.
     Virchows Arch, 455(2): 109-15. [Abstract] [Full-text]
146. Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification.
     Virchows Arch, 455(2): 117-23. [Abstract] [Full-text]
147. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
     Genes Dev, 23(16): 1882-94. [Abstract] [Full-text]
148. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation.
     J Biol Chem, 284(34): 23094-106. [Abstract] [Full-text]
149. Is red meat intake a risk factor for breast cancer among premenopausal women?
     Breast Cancer Res Treat, 117(1): 1-8. [Abstract] [Full-text]
150. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation.
     Hum Reprod, 24(9): 2238-43. [Abstract] [Full-text]
151. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
     Hum Pathol, 40(9): 1224-33. [Abstract] [Full-text]
152. Breast cancer risk in relation to the joint effect of BRCA mutations and diet diversity.
     Breast Cancer Res Treat, 117(2): 417-22. [Abstract] [Full-text]
153. Seed in soil, with an epigenetic view.
     Biochim Biophys Acta, 1790(9): 920-4. [Abstract] [Full-text]
154. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China.
     Breast Cancer Res Treat, 117(2): 409-16. [Abstract] [Full-text]
155. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO).
     Breast Cancer Res Treat, 117(2): 333-8. [Abstract] [Full-text]
156. Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables.
     Breast Cancer Res Treat, 117(2): 325-31. [Abstract] [Full-text]
157. An educational video to increase clinical trials enrollment among breast cancer patients.
     Breast Cancer Res Treat, 117(2): 339-47. [Abstract] [Full-text]
158. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model.
     Breast Cancer Res Treat, 117(2): 401-8. [Abstract] [Full-text]
159. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis.
     Breast Cancer Res Treat, 117(2): 391-9. [Abstract] [Full-text]
160. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
     Breast Cancer Res Treat, 117(2): 319-24. [Abstract] [Full-text]
161. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients.
     Breast Cancer Res Treat, 117(2): 297-303. [Abstract] [Full-text]
162. Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model.
     Breast Cancer Res Treat, 117(2): 305-17. [Abstract] [Full-text]
163. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
     Breast Cancer Res Treat, 117(2): 289-95. [Abstract] [Full-text]
164. Kwan's arm problem scale: psychometric examination in a sample of stage II breast cancer survivors.
     Breast Cancer Res Treat, 117(2): 281-8. [Abstract] [Full-text]
165. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
     Breast Cancer Res Treat, 117(1): 91-8. [Abstract] [Full-text]
166. Plasma carotenoids, tocopherols, retinol and breast cancer risk: results from the Shanghai Women Health Study (SWHS).
     Breast Cancer Res Treat, 117(2): 381-9. [Abstract] [Full-text]
167. No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
     Breast Cancer Res Treat, 117(2): 371-9. [Abstract] [Full-text]
168. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
     Breast Cancer Res Treat, 117(2): 357-64. [Abstract] [Full-text]
169. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence.
     Breast Cancer Res Treat, 117(2): 365-70. [Abstract] [Full-text]
170. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
     Breast Cancer Res Treat, 117(1): 83-9. [Abstract] [Full-text]
171. Appropriateness of early breast cancer management in relation to patient and hospital characteristics: a population based study in Northern Italy.
     Breast Cancer Res Treat, 117(2): 349-56. [Abstract] [Full-text]
172. Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant.
     Breast Cancer Res Treat, 117(1): 77-81. [Abstract] [Full-text]
173. Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.
     Breast Cancer Res Treat, 117(1): 167-76. [Abstract] [Full-text]
174. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
     Breast Cancer Res Treat, 117(1): 69-75. [Abstract] [Full-text]
175. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
     Breast Cancer Res Treat, 117(1): 161-5. [Abstract] [Full-text]
176. Low penetrance breast cancer predisposition SNPs are site specific.
     Breast Cancer Res Treat, 117(1): 151-9. [Abstract] [Full-text]
177. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis.
     Breast Cancer Res Treat, 117(1): 141-50. [Abstract] [Full-text]
178. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
     Breast Cancer Res Treat, 117(1): 131-40. [Abstract] [Full-text]
179. Analysis of the effect of age on the prognosis of breast cancer.
     Breast Cancer Res Treat, 117(1): 121-9. [Abstract] [Full-text]
180. Breast cancer survivors who use estrogenic botanical supplements have lower serum estrogen levels than non users.
     Breast Cancer Res Treat, 117(1): 111-9. [Abstract] [Full-text]
181. Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial).
     Breast Cancer Res Treat, 117(1): 99-109. [Abstract] [Full-text]
182. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
     Breast Cancer Res Treat, 117(2): 261-71. [Abstract] [Full-text]
183. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis.
     Breast Cancer Res Treat, 117(2): 273-80. [Abstract] [Full-text]
184. Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer.
     Breast Cancer Res Treat, 117(2): 253-9. [Abstract] [Full-text]
185. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
     Breast Cancer Res Treat, 117(2): 243-51. [Abstract] [Full-text]
186. Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients.
     Breast Cancer Res Treat, 117(2): 227-33. [Abstract] [Full-text]
187. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
     Breast Cancer Res Treat, 117(1): 45-54. [Abstract] [Full-text]
188. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro.
     Breast Cancer Res Treat, 117(1): 31-44. [Abstract] [Full-text]
189. Genomic instability demonstrates similarity between DCIS and invasive carcinomas.
     Breast Cancer Res Treat, 117(1): 17-24. [Abstract] [Full-text]
190. When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.
     Breast Cancer Res Treat, 117(1): 25-9. [Abstract] [Full-text]
191. Vitreo-retinal traction and anastrozole use.
     Breast Cancer Res Treat, 117(1): 9-16. [Abstract] [Full-text]
192. Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases.
     Breast Cancer Res Treat, 117(2): 453-9. [Abstract] [Full-text]
193. Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma.
     Breast Cancer Res Treat, 117(2): 433-41. [Abstract] [Full-text]
194. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
     Breast Cancer Res Treat, 117(2): 443-51. [Abstract] [Full-text]
195. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.
     Breast Cancer Res Treat, 117(1): 61-8. [Abstract] [Full-text]
196. Clinical applications of the superior epigastric artery perforator (SEAP) flap: anatomical studies and preoperative perforator mapping with multidetector CT.
     J Plast Reconstr Aesthet Surg, 62(9): 1127-34. [Abstract] [Full-text]
197. Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.
     Breast Cancer Res Treat, 117(1): 211-4. [Abstract] [Full-text]
198. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer.
     Breast Cancer Res Treat, 117(1): 205-10. [Abstract] [Full-text]
199. Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status.
     Breast Cancer Res Treat, 117(1): 199-204. [Abstract] [Full-text]
200. Lobular involution: localized phenomenon or field effect?
     Breast Cancer Res Treat, 117(1): 193-6. [Abstract] [Full-text]
201. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.
     Breast Cancer Res Treat, 117(1): 183-91. [Abstract] [Full-text]
202. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer.
     Breast Cancer Res Treat, 117(1): 55-60. [Abstract] [Full-text]
203. The association of breast cancer and meningioma in men and women.
     Neurosurgery, 65(3): 483-9; discussion 489. [Abstract] [Full-text]
204. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results.
     Am J Clin Pathol, 132(3): 396-401. [Abstract] [Full-text]
205. Primary lung cancer vs metastatic breast cancer: a probabilistic approach.
     Am J Clin Pathol, 132(3): 391-5. [Abstract] [Full-text]
206. Implication of protein tyrosine phosphatase 1B in MCF-7 cell proliferation and resistance to 4-OH tamoxifen.
     Biochem Biophys Res Commun, 387(4): 748-53. [Abstract] [Full-text]
207. Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer.
     J Cancer Res Clin Oncol, 135(10): 1393-401. [Abstract] [Full-text]
208. Network-assisted protein identification and data interpretation in shotgun proteomics.
     Mol Syst Biol, 5: 303. [Abstract] [Full-text]
209. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
     JAMA, 302(7): 774-80. [Abstract] [Full-text]
210. Follow-up may not be beneficial after treatment of grade 1 breast cancer.
     Br J Surg, 96(9): 999-1004. [Abstract] [Full-text]
211. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
     J Clin Oncol, 27(24): 3908-15. [Abstract] [Full-text]
212. Lung dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation using three-dimensional conformal radiotherapy.
     J Clin Oncol, 27(24): 3887-93. [Abstract] [Full-text]
213. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
     J Clin Oncol, 27(24): 3881-6. [Abstract] [Full-text]
214. Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers.
     J Clin Oncol, 27(24): 3894-900. [Abstract] [Full-text]
215. Radiation dose and breast cancer risk in the childhood cancer survivor study.
     J Clin Oncol, 27(24): 3901-7. [Abstract] [Full-text]
216. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer.
     J Clin Oncol, 27(24): 3945-50. [Abstract] [Full-text]
217. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
     Cancer Immunol Immunother, 58(11): 1887-96. [Abstract] [Full-text]
218. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.
     Cancer Chemother Pharmacol, 64(6): 1139-48. [Abstract] [Full-text]
219. Non-Hodgkin's lymphoma of supraclavicular lymph nodes can mimic metastasis of breast cancer during chemotherapy on FDG PET/CT.
     Clin Nucl Med, 34(9): 594-5. [Abstract] [Full-text]
220. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
     N Engl J Med, 361(8): 766-76. [Abstract] [Full-text]
221. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results.
     Invest Radiol, 44(9): 553-8. [Abstract] [Full-text]
222. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.
     Oncogene, 28(33): 2940-7. [Abstract] [Full-text]
223. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer.
     Oncogene, 28(33): 2948-58. [Abstract] [Full-text]
224. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
     Cancer Cytopathol, 117(4): 279-88. [Abstract] [Full-text]
225. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells.
     Oncogene, 28(33): 2979-87. [Abstract] [Full-text]
226. Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array.
     Oncogene, 28(33): 2969-78. [Abstract] [Full-text]
227. Mammary fibromatosis.
     AJR Am J Roentgenol, 193(3): 856-60. [Abstract] [Full-text]
228. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy?
     AJR Am J Roentgenol, 193(3): 840-9. [Abstract] [Full-text]
229. Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition.
     AJR Am J Roentgenol, 193(3): 832-9. [Abstract] [Full-text]
230. MRI-detected suspicious breast lesions: predictive values of kinetic features measured by computer-aided evaluation.
     AJR Am J Roentgenol, 193(3): 826-31. [Abstract] [Full-text]
231. Accounts of disruptions to sexuality following cancer: the perspective of informal carers who are partners of a person with cancer.
     Health (London), 13(5): 523-41. [Abstract] [Full-text]
232. Centre credentialing for Trans Tasman Radiation Oncology Group trial 06.02: multicentre feasibility study of accelerated partial breast irradiation.
     J Med Imaging Radiat Oncol, 53(4): 412-8. [Abstract] [Full-text]
233. MRI guidance for accelerated partial breast irradiation in prone position: imaging protocol design and evaluation.
     Int J Radiat Oncol Biol Phys, 75(1): 285-93. [Abstract] [Full-text]
234. Gastrin-releasing peptide receptor in breast cancer mediates cellular migration and interleukin-8 expression.
     J Surg Res, 156(1): 26-31. [Abstract] [Full-text]
235. Dietary fiber intake and risk of breast cancer in postmenopausal women: the National Institutes of Health-AARP Diet and Health Study.
     Am J Clin Nutr, 90(3): 664-71. [Abstract] [Full-text]
236. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.
     Cancer Sci, 100(9): 1748-56. [Abstract] [Full-text]
237. Dietary patterns and breast cancer risk in women participating in the Black Women's Health Study.
     Am J Clin Nutr, 90(3): 621-8. [Abstract] [Full-text]
238. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells.
     Cancer Sci, 100(9): 1719-27. [Abstract] [Full-text]
239. Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer.
     Cancer Sci, 100(9): 1767-71. [Abstract] [Full-text]
240. Accelerated partial breast irradiation: what is dosimetric effect of advanced technology approaches?
     Int J Radiat Oncol Biol Phys, 75(1): 294-301. [Abstract] [Full-text]
241. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines.
     Cancer Sci, 100(9): 1668-74. [Abstract] [Full-text]
242. Midkine in plasma as a novel breast cancer marker.
     Cancer Sci, 100(9): 1735-9. [Abstract] [Full-text]
243. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
     Cancer Sci, 100(9): 1663-7. [Abstract] [Full-text]
244. Conjugated linoleic acid intake and breast cancer risk in a prospective cohort of Swedish women.
     Am J Clin Nutr, 90(3): 556-60. [Abstract] [Full-text]
245. Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
     Am J Clin Nutr, 90(3): 602-12. [Abstract] [Full-text]
246. Change in seroma volume during whole-breast radiation therapy.
     Int J Radiat Oncol Biol Phys, 75(1): 89-93. [Abstract] [Full-text]
247. Individual positioning: a comparative study of adjuvant breast radiotherapy in the prone versus supine position.
     Int J Radiat Oncol Biol Phys, 75(1): 94-100. [Abstract] [Full-text]
248. Does three-dimensional external beam partial breast irradiation spare lung tissue compared with standard whole breast irradiation?
     Int J Radiat Oncol Biol Phys, 75(1): 82-8. [Abstract] [Full-text]
249. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy.
     Int J Radiat Oncol Biol Phys, 75(1): 76-81. [Abstract] [Full-text]
250. Biological determinants of endocrine resistance in breast cancer.
     Nat Rev Cancer, 9(9): 631-43. [Abstract] [Full-text]
251. Increasing incidence of pregnancy-associated breast cancer in Sweden.
     Obstet Gynecol, 114(3): 568-72. [Abstract] [Full-text]
252. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer.
     Eur J Cancer, 45(13): 2239-48. [Abstract] [Full-text]
253. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines.
     Mol Immunol, 46(15): 2931-7. [Abstract] [Full-text]
254. Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer.
     BMC Womens Health, 9: 20. [Abstract] [Full-text]
255. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
     Eur J Cancer, 45(13): 2274-83. [Abstract] [Full-text]
256. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells.
     J Biol Chem, 284(35): 23204-16. [Abstract] [Full-text]
257. Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling.
     Chem Biol Interact, 181(2): 263-71. [Abstract] [Full-text]
258. Does the new automated "HALO" nipple aspiration fluid system really deliver as promised? The answer is "No, but...": A literature review of the role of breast fluid cytology in cancer risk assessment.
     Diagn Cytopathol, 37(9): 699-704. [Abstract] [Full-text]
259. Ultrasonography-guided core needle biopsy in differential diagnosis of papillary breast tumors.
     Acta Radiol, 50(7): 722-9. [Abstract] [Full-text]
260. Capecitabine and vinorelbine in metastatic breast cancer.
     Eur J Cancer, 45(13): 2253-65. [Abstract] [Full-text]
261. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.
     Eur J Cancer, 45(13): 2284-92. [Abstract] [Full-text]
262. Efficacy of fine-needle aspiration biopsy in diagnosis of breast cancer: a retrospective study of 303 cases in Bahrain.
     Diagn Cytopathol, 37(9): 636-40. [Abstract] [Full-text]
263. Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding.
     Eur J Cancer, 45(13): 2376-82. [Abstract] [Full-text]
264. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?
     Diagn Mol Pathol, 18(3): 125-32. [Abstract] [Full-text]
265. Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features.
     Radiology, 252(2): 358-68. [Abstract] [Full-text]
266. Cancer cases from ACRIN digital mammographic imaging screening trial: radiologist analysis with use of a logistic regression model.
     Radiology, 252(2): 348-57. [Abstract] [Full-text]
267. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer.
     Cell, 138(4): 660-72. [Abstract] [Full-text]
268. Breast cancer stem cells: eradication by differentiation therapy?
     Cell, 138(4): 623-5. [Abstract] [Full-text]
269. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
     APMIS, 117(9): 644-50. [Abstract] [Full-text]
270. Does preoperative core needle biopsy increase surgical site infections in breast cancer surgery? Randomized study of antibiotic prophylaxis.
     Surg Infect (Larchmt), 10(4): 317-21. [Abstract] [Full-text]
271. The influence of black race on treatment and mortality for early-stage breast cancer.
     Med Care, 47(9): 986-92. [Abstract] [Full-text]
272. Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer.
     Cytokine, 47(3): 214-23. [Abstract] [Full-text]
273. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes.
     Radiology, 252(2): 551-60. [Abstract] [Full-text]
274. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
     Ann Oncol, 20(9): 1489-98. [Abstract] [Full-text]
275. Inequalities in breast cancer stage at diagnosis in the Trent region, and implications for the NHS Breast Screening Programme.
     J Public Health (Oxf), 31(3): 398-405. [Abstract] [Full-text]
276. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
     Ann Oncol, 20(9): 1499-504. [Abstract] [Full-text]
277. Early detection of second breast cancers improves prognosis in breast cancer survivors.
     Ann Oncol, 20(9): 1505-10. [Abstract] [Full-text]
278. Deubiquitinating enzyme USP33/VDU1 is required for Slit signaling in inhibiting breast cancer cell migration.
     Proc Natl Acad Sci U S A, 106(34): 14530-5. [Abstract] [Full-text]
279. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.
     Proc Natl Acad Sci U S A, 106(33): 14028-33. [Abstract] [Full-text]
280. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.
     Proc Natl Acad Sci U S A, 106(33): 13820-5. [Abstract] [Full-text]
281. CT-X antigen expression in human breast cancer.
     Proc Natl Acad Sci U S A, 106(32): 13493-8. [Abstract] [Full-text]
282. Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors.
     Cancer, 115(17): 4001-9. [Abstract] [Full-text]
283. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression.
     Int J Cancer, 125(8): 1778-85. [Abstract] [Full-text]
284. FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: results of a case control study in Japan.
     Int J Cancer, 125(8): 1946-52. [Abstract] [Full-text]
285. Parity and age at first childbirth in relation to the risk of different breast cancer subgroups.
     Int J Cancer, 125(8): 1926-34. [Abstract] [Full-text]
286. TOB suppresses breast cancer tumorigenesis.
     Int J Cancer, 125(8): 1805-13. [Abstract] [Full-text]
287. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women.
     Cancer, 115(17): 3848-57. [Abstract] [Full-text]
288. The effect of credibility-related design cues on responses to a web-based message about the breast cancer risks from alcohol: randomized controlled trial.
     J Med Internet Res, 11(3): e37. [Abstract] [Full-text]
289. Low-dose radiation-induced senescent stromal fibroblasts render nearby breast cancer cells radioresistant.
     Radiat Res, 172(3): 306-13. [Abstract] [Full-text]
290. Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
     J Mol Diagn, 11(5): 381-9. [Abstract] [Full-text]
291. Candidate mechanisms accounting for effects of physical activity on breast carcinogenesis.
     IUBMB Life, 61(9): 895-901. [Abstract] [Full-text]
292. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration.
     Oncogene, 28(34): 3047-57. [Abstract] [Full-text]
293. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases.
     Oncogene, 28(34): 3022-32. [Abstract] [Full-text]
294. Mastopathic-type fibroadenoma and ductal adenoma of the breast with false-positive fluorodeoxyglucose positron emission tomography.
     Jpn J Radiol, 27(7): 280-4. [Abstract] [Full-text]
295. Cardiac-sparing radiotherapy for the left breast cancer with deep breath-holding.
     Jpn J Radiol, 27(7): 259-63. [Abstract] [Full-text]
296. Local relapse after breast-conserving surgery and radiotherapy: effects on survival parameters.
     Strahlenther Onkol, 185(7): 431-7. [Abstract] [Full-text]
297. Effect of breathing motion in radiotherapy of breast cancer: 4D dose calculation and motion tracking via EPID.
     Strahlenther Onkol, 185(7): 425-30. [Abstract] [Full-text]
298. DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC).
     Strahlenther Onkol, 185(7): 417-24. [Abstract] [Full-text]
299. Magnetic resonance appearance of granular cell tumor of the breast.
     Clin Imaging, 33(5): 395-7. [Abstract] [Full-text]
300. Angle between 1 and 4 min gives the most significant difference in time-intensity curves between benign disease and breast cancer: analysis of dynamic magnetic resonance imaging in 103 patients with breast lesions.
     Clin Imaging, 33(5): 335-42. [Abstract] [Full-text]
301. Metaplastic breast carcinoma with melanocytic differentiation.
     Pathol Int, 59(9): 676-80. [Abstract] [Full-text]
302. Spontaneous regression of primary breast lymphoma.
     Pathol Int, 59(9): 664-9. [Abstract] [Full-text]
303. Initial characterization of a dedicated breast PET/CT scanner during human imaging.
     J Nucl Med, 50(9): 1401-8. [Abstract] [Full-text]
304. Fusion of MRI and sonography image for breast cancer evaluation using real-time virtual sonography with magnetic navigation: first experience.
     Jpn J Clin Oncol, 39(9): 552-9. [Abstract] [Full-text]
305. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.
     Jpn J Clin Oncol, 39(9): 560-8. [Abstract] [Full-text]
306. Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer.
     Mol Endocrinol, 23(9): 1397-405. [Abstract] [Full-text]
307. Outcome of multiple-wire localization for larger breast cancers: do multiple wires translate into additional imaging, biopsies, and recurrences?
     Am J Surg, 198(3): 368-72. [Abstract] [Full-text]
308. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomised controlled trial.
     Lancet Oncol, 10(9): 849-54. [Abstract] [Full-text]
309. Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment.
     J Clin Oncol, 27(25): 4182-7. [Abstract] [Full-text]
310. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging.
     J Clin Oncol, 27(25): 4082-8. [Abstract] [Full-text]
311. Estrogen inhibits glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor dephosphorylation.
     J Biol Chem, 284(36): 24542-52. [Abstract] [Full-text]
312. US surveillance of regional lymph node recurrence after breast cancer surgery.
     Radiology, 252(3): 673-81. [Abstract] [Full-text]
313. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion.
     Cancer Lett, 284(1): 80-5. [Abstract] [Full-text]
314. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells.
     Cancer Lett, 284(1): 47-54. [Abstract] [Full-text]
315. Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer.
     Am J Surg, 198(3): 387-91. [Abstract] [Full-text]

© 2004-2010 Breast Cancer Research Today. All Rights Reserved.